CD16 (Fc RIIIa), the low affinity receptor for IgG, expressed by the majority of human natural killer (NK) cells, is a potent activating receptor that facilitates antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC dysfunction has been linked to cancer progression and poor prognosis for chronic infections, such as HIV; thus, understanding how CD16 expression is regulated by NK cells has clinical relevance. Importantly, CD16 cell-surface expression is down-modulated following NK cell activation and, in particular, exposure to stimulatory cytokines (IL-2 or IL-15), likely due to the action of matrix metalloproteinases (MMPs). Here, we identify membrane-type 6 matrix metalloproteinase (MT6, also known as MMP25) as a proteinase responsible for CD16 down-modulation. IL-2-induced up-regulation of MT6/MMP25 cell surface expression correlates with CD16 down-modulation. MT6/MMP25, sequestered in intracellular compartments in unstimulated NK cells, translocates to the cell surface after stimulation; moreover it polarizes to the effector-target cell interface of the CD16-mediated immunological synapse. siRNA-mediated disruption of MT6/MMP25 expression enhances the ADCC capacity of NK cells, emphasizing the important functional role of MT6/MMP25 in the regulation of ADCC activity. Thus, this study uncovers a previously unknown role of MT6/MMP25 in human NK cells, and suggests that inhibition of MT6/MMP25 activity could improve ADCC efficacy of therapeutically administered NK cells that require IL-2 for culture and expansion.

CD16 (FcgammaRIIIa), the low affinity receptor for IgG is a potent activating receptor expressed by the majority of human natural killer (NK) cells that functions to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Since the bound IgG can be exchanged, the target cell recognition through CD16 gives NK cells flexibility in receptor specificity that can be manipulated for therapeutic purposes. ADCC dysfunction has been linked to cancer progression, poor prognosis and chronic infections; thus, understanding how CD16 expression is regulated by NK cells has clinical relevance. It is well established that upon activation NK cells enter into a refractory period in which CD16 expression is dramatically down-modulated, mainly due to the action of matrix metalloproteinases (MMPs). The aim of this project is to identify the MMP(s) responsible for CD16 cell surface down-modulation on activated NK cells and to determine if this down-modulation can be inhibited. Our data indicate that CD16 is down-modulated upon cell activation in primary NK cells, the released CD16 can be detected in the supernatant of the activated cells and a membrane-type MMP is involved in the process of CD16 shedding.